Home / Directory / Regulatory Affairs & Submissions / eCTD Submission Publishing & Validation

Regulatory Affairs & Submissions · Healthcare & Life Sciences

Should you build or buy eCTD Submission Publishing & Validation?

eCTD submission publishing and validation software handles the assembly, formatting, sequencing, and technical validation of electronic Common Technical Document dossiers submitted to regulatory authorities including the FDA, EMA, and PMDA. It converts compiled regulatory content into authority-conformant submission packages and runs validation checks against published ICH and health-authority specifications before filing.

The build-vs-buy decision for eCTD Submission Publishing and Validation turns on how much competitive advantage you can extract from a category where the submission format itself is fully standardized by ICH, and how far open-source and AI-assisted tooling has come at covering the validation and dossier assembly logic; the specifics of your submission volume and engineering capacity decide it.

Build it, buy it, or bridge?

⚒ Build it
✓ Buy it
➔ Bridge
Cost shape
Engineering cost offset by avoiding per-submission licensing at scale
Predictable subscription or per-submission fees; no infrastructure overhead
License core platform; extend with internal automation for high-volume workflows
Time to value
Weeks to cover core validation; longer to match lifecycle management features
Days to deploy; vendor handles authority-specific variant rules immediately
Rapid baseline deployment; layer custom automation as volume justifies it
Differentiation captured
None on format compliance; potential advantage on FHIR transition architecture
Compliance is the product; vendors invest in authority updates continuously
Same compliance baseline as buy; customization on workflow automation only
AI feasibility today
FDA validation rules are published; AI gap analysis tools are maturing; ~50-70% of core buildable
Vendors adding AI-assisted gap checking; faster release of authority update changes
Buy the validated backbone; add AI-assisted content review and gap analysis on top
Who it fits
High-volume CROs with engineering staff and desire to avoid per-submission fees
Most sponsors who need reliable, audit-ready lifecycle management without infrastructure
Sponsors anticipating FHIR transition and wanting flexibility without a full rebuild

When building makes sense

The build case for eCTD publishing is most credible for CROs or large sponsors with very high submission volume, engineering resources willing to maintain the pipeline against ongoing health authority updates, and a desire to avoid per-submission licensing fees that compound at scale. The underlying validation logic is unusually transparent: the ICH validation criteria are published, the FDA's own validation utilities are publicly available, and AI-assisted gap analysis has matured to the point where covering the core validation workflow is achievable without a commercial platform. The stronger strategic argument is forward-looking — organizations building now can architect for the FHIR-based submission transition in a way that legacy vendor platforms may be slower to support, giving them a structural advantage as that standard rolls out across authorities.

When buying makes sense

Buying makes sense for the large majority of sponsors who need reliable dossier assembly and lifecycle management across multiple health authorities without building the full stack. The format is standardized, but managing authority-specific submission variants for FDA, EMA, PMDA, Health Canada, and others simultaneously is operationally complex. Vendors like LORENZ docuBridge and Certara GlobalSubmit absorb the maintenance cost of tracking regulatory change across those jurisdictions — when ICH guidance updates, the vendor ships the change rather than routing it to internal engineering. Buying also makes sense when submission volume is too low to justify the infrastructure investment, or when the team needs the audit trail and lifecycle management features that commercial platforms have refined over years of production use.

The desk read

eCTD format is defined entirely by ICH standards (v3.2.2 and v4.0) and health authority specifications. The validation rules are published, the dossier structure is standardized, and the FDA's own validation utilities are publicly available. That published specification is what makes this category unusual: the compliance requirements are not proprietary, they're open, and several teams have built internal pipelines or CRO-specific tools covering significant portions of the core workflow. Platforms like LORENZ docuBridge, Ennov, and Certara GlobalSubmit compete in a space where the underlying logic is documented.

Buying still earns its keep for sponsors who need lifecycle management, health authority-specific submission variants (EMA, PMDA, Health Canada), and audit-ready workflows without building the full stack. The buy case weakens at the margins as AI-assisted gap analysis matures and open-source tooling improves. The build case is most credible for CROs with high submission volume, the engineering resources to maintain the pipeline against evolving health authority requirements, and a desire to avoid per-submission licensing fees. The transition to FHIR-based submissions adds another variable: organizations building now can architect for that transition in a way that vendor platforms may be slower to accommodate.

Representative vendors LORENZ docuBridgeEnnov + 3 more, scored in Pro

Frequently asked

What is eCTD Submission Publishing and Validation software?

eCTD submission publishing and validation software handles the assembly, formatting, sequencing, and technical validation of electronic Common Technical Document dossiers submitted to regulatory authorities including the FDA, EMA, and PMDA. It converts compiled regulatory content into authority-conformant submission packages and runs validation checks against published ICH specifications before filing.

When does building eCTD Submission Publishing make sense?

Building is most credible for high-volume CROs with engineering staff who want to avoid per-submission fees and have the capacity to maintain the pipeline against evolving authority requirements. Teams building now can also architect for the FHIR-based submission transition in a way legacy vendor platforms may be slower to accommodate.

When does buying eCTD Submission Publishing make sense?

Buying makes sense when you need reliable, multi-authority dossier assembly and lifecycle management without building and maintaining the full stack. Vendors absorb the ongoing cost of tracking regulatory changes across FDA, EMA, PMDA, and Health Canada simultaneously.

What are the main eCTD Submission Publishing vendors?

Representative vendors include LORENZ docuBridge, Ennov, EXTEDO eCTDmanager, Certara GlobalSubmit. B4 Pro scores the full set.

How does the shift to FHIR-based submissions affect this decision?

The ongoing transition to FHIR-based submissions is a meaningful variable. Organizations building their own publishing pipelines can architect for that transition directly, while legacy vendor platforms may carry technical debt from the older eCTD format that slows FHIR adoption. It's one of the few areas where a self-built approach offers a structural advantage over established vendors.

The B4 Index scores every software category on two axes, strategic differentiation and AI feasibility, to classify it Build, Buy, Bridge, or Beware. See the full methodology.